Explore the Agenda
7:55 am Morning Check-In: Served with coffee + light breakfast
8:25 am Chair’s Opening Remarks
Aligning Science, Strategy & Stakeholders To Accelerate Commercial Translation In Dermatology Drug Development
9:00 am Panel Discussion: Bridging Science and Strategy: Funding the Next Wave of Dermatology Innovation
- Trends in capital allocation across indications, modalities, and stages of development in dermatology
- Key factors that shape investor and pharma conviction in early-stage assets and platforms
- How clinical trial design, endpoints, and market access considerations influence fundability
- Strategies for building successful partnerships and aligning with pharma and investor expectations
9:30 am Early Phase Clinical Trials: Proof-of Mechanism in Healthy Volunteers & Patients
- Introduction to pharmacological challenge models in healthy volunteers
- Proof-of-mechanism in healthy participants and patients
- Case studies with multimodal (imaging) read out
- Deep phenotyping of atopic dermatitis, psoriasis and T-cell lymphoma
10:00 am Morning Break & Refreshments
Innovative Pathways & Novel Modalities Driving The Next Wave Of Inflammatory Skin Disease Therapeutics
10:30 am TIRmed’s TIR‑C: Advancing Topical Oligonucleotide Therapy for Atopic Dermatitis into the Clinic
- TIR‑C aims to relieve itch and regenerate tissue without systemic side effects, thereby directly modulating skin immune cells (e.g., dendritic, mast cells, IL‑10 induction)
- Outlining nonclinical toxicology and regulatory approaches for CTA approval ahead of planned Phase I trial in 2026
- After Phase I safety and tolerability results TIRmed will prepare for Phase Ib targeting efficacy in mild-to-moderate AD positioning the program as a second line treatment after corticosteroids
11:00 am SFA-002: A Novel Oral Drug for Treating Autoimmune Disease: Results in Psoriasis
- Outlining SFA-002 mechanism of action by immunomodulation over immunosuppression
- Preclinical, phase Ia and phase Ib efficacy findings
- Safety profile
- Durable responses
- Special populations – scalp/palmoplantar psoriasis cohorts
- Differentiation strategy: convenience, cost, and multi-pathway modulation
11:30 am Transforming Supportive Oncology Care: Innovative Skin-Directed Targeted Therapies for EGFR Inhibitor Induced Inflammation
- First-in-Class Skin-Directed Prevention — blocking EGFRi on-target toxicities before skin inflammation occurs.
- Follicular-Focused Drug Delivery — maximizing local efficacy while minimizing systemic exposure.
- Targeting Rare Dermatologic Diseases — addressing high unmet medical need with limited treatment options.
12:00 pm Lunch & Networking
No day selected
R&D Track
Innovaiton in Science
Innovating in Receptor Designs & Novel Targets to Increase Efficacy in Difficult Indications
11:30 am Advancing Next-Generation TCR Therapies Targeting ROPN1 to Address Triple-Negative Breast Cancer
12:00 pm Development of TCR Technology Platforms for Cancer Immunotherapy
Manufacturing Track
Realising Scale & Access
Overcoming Analytical Bottlenecks for Reliable Product Release
11:30 am Reserved for Klinea Biotech & Pharma Engineering
11:40 am Standardising CAR T-Cell Monitoring to Improve Clinical Insights & Translational Outcomes
12:30 pm Lunch & Networking Break
R&D Track
Innovaiton in Science
Leveraging Armouring & Combination Approaches to Overcome Solid Tumour Barriers & Unlock Durable Responses
1:30 pm CARKey: a CAR-T Platform to Mitigate Tumour Antigen Heterogeneity & On-Target-off Tumour Toxicity
2:00 pm STAb-T Cells: Bridging Cell Therapy & Bispecific Antibodies for Sustained Antitumour Immunity
Manufacturing Track
Realising Scale & Access
Driving Lean Manufacturing to Reduce Costs & Accelerate Timelines
1:30 pm Panel Discussion: Manufacturing Leaner & More Affordably to Accelerate Cell Therapy Development in Europe
2:00 pm Driving Efficiency & Unlocking Scalability for PRAME Cell Therapy Manufacturing
R&D Track Innovation in Science
Innovating in Receptor Designs & Novel Targets to Increase Efficacy in Difficult Indications
11:30 am Advancing Next-Generation TCR Therapies Targeting ROPN1 to Address Triple-Negative Breast Cancer
12:00 pm Development of TCR Technology Platforms for Cancer Immunotherapy
Manufacturing Track Realising Scale & Access
Track Name
Track Name
12:30 pm Lunch & Networking Break
R&D Track Innovation in Science
Leveraging Armouring & Combination Approaches to Overcome Solid Tumour Barriers & Unlock Durable Responses
1:30 pm CARKey: a CAR-T Platform to Mitigate Tumour Antigen Heterogeneity & On-Target-off Tumour Toxicity
2:00 pm STAb-T Cells: Bridging Cell Therapy & Bispecific Antibodies for Sustained Antitumour Immunity
Manufacturing Track Realising Scale & Access
Track Name
Track Name